JP2010513506A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010513506A5 JP2010513506A5 JP2009542880A JP2009542880A JP2010513506A5 JP 2010513506 A5 JP2010513506 A5 JP 2010513506A5 JP 2009542880 A JP2009542880 A JP 2009542880A JP 2009542880 A JP2009542880 A JP 2009542880A JP 2010513506 A5 JP2010513506 A5 JP 2010513506A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- polypeptide
- amino acid
- acid sequence
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87568206P | 2006-12-18 | 2006-12-18 | |
| US60/875,682 | 2006-12-18 | ||
| PCT/US2007/025868 WO2008076437A2 (en) | 2006-12-18 | 2007-12-18 | Activin-actrii antagonists and uses for increasing red blood cell levels |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013055102A Division JP5865281B2 (ja) | 2006-12-18 | 2013-03-18 | アクチビン−ＡｃｔＲＩＩアンタゴニストおよび赤血球レベルを増加させるためのその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010513506A JP2010513506A (ja) | 2010-04-30 |
| JP2010513506A5 true JP2010513506A5 (enExample) | 2012-02-09 |
| JP5415279B2 JP5415279B2 (ja) | 2014-02-12 |
Family
ID=39183159
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009542880A Active JP5415279B2 (ja) | 2006-12-18 | 2007-12-18 | アクチビン−ＡｃｔＲＩＩアンタゴニストおよび赤血球レベルを増加させるためのその使用 |
| JP2013055102A Active JP5865281B2 (ja) | 2006-12-18 | 2013-03-18 | アクチビン−ＡｃｔＲＩＩアンタゴニストおよび赤血球レベルを増加させるためのその使用 |
| JP2013243668A Pending JP2014040483A (ja) | 2006-12-18 | 2013-11-26 | アクチビン−ＡｃｔＲＩＩアンタゴニストおよび赤血球レベルを増加させるためのその使用 |
| JP2015211115A Pending JP2016020391A (ja) | 2006-12-18 | 2015-10-27 | アクチビン−ＡｃｔＲＩＩアンタゴニストおよび赤血球レベルを増加させるためのその使用 |
| JP2017018409A Pending JP2017075187A (ja) | 2006-12-18 | 2017-02-03 | アクチビン−ＡｃｔＲＩＩアンタゴニストおよび赤血球レベルを増加させるためのその使用 |
| JP2017119494A Withdrawn JP2017155064A (ja) | 2006-12-18 | 2017-06-19 | アクチビン−ＡｃｔＲＩＩアンタゴニストおよび赤血球レベルを増加させるためのその使用 |
| JP2019044553A Withdrawn JP2019089850A (ja) | 2006-12-18 | 2019-03-12 | アクチビン−ＡｃｔＲＩＩアンタゴニストおよび赤血球レベルを増加させるためのその使用 |
| JP2021032007A Pending JP2021080290A (ja) | 2006-12-18 | 2021-03-01 | アクチビン−ＡｃｔＲＩＩアンタゴニストおよび赤血球レベルを増加させるためのその使用 |
Family Applications After (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013055102A Active JP5865281B2 (ja) | 2006-12-18 | 2013-03-18 | アクチビン−ＡｃｔＲＩＩアンタゴニストおよび赤血球レベルを増加させるためのその使用 |
| JP2013243668A Pending JP2014040483A (ja) | 2006-12-18 | 2013-11-26 | アクチビン−ＡｃｔＲＩＩアンタゴニストおよび赤血球レベルを増加させるためのその使用 |
| JP2015211115A Pending JP2016020391A (ja) | 2006-12-18 | 2015-10-27 | アクチビン−ＡｃｔＲＩＩアンタゴニストおよび赤血球レベルを増加させるためのその使用 |
| JP2017018409A Pending JP2017075187A (ja) | 2006-12-18 | 2017-02-03 | アクチビン−ＡｃｔＲＩＩアンタゴニストおよび赤血球レベルを増加させるためのその使用 |
| JP2017119494A Withdrawn JP2017155064A (ja) | 2006-12-18 | 2017-06-19 | アクチビン−ＡｃｔＲＩＩアンタゴニストおよび赤血球レベルを増加させるためのその使用 |
| JP2019044553A Withdrawn JP2019089850A (ja) | 2006-12-18 | 2019-03-12 | アクチビン−ＡｃｔＲＩＩアンタゴニストおよび赤血球レベルを増加させるためのその使用 |
| JP2021032007A Pending JP2021080290A (ja) | 2006-12-18 | 2021-03-01 | アクチビン−ＡｃｔＲＩＩアンタゴニストおよび赤血球レベルを増加させるためのその使用 |
Country Status (30)
| Country | Link |
|---|---|
| US (7) | US7988973B2 (enExample) |
| EP (6) | EP2124999B1 (enExample) |
| JP (8) | JP5415279B2 (enExample) |
| KR (6) | KR101831534B1 (enExample) |
| CN (4) | CN105797135A (enExample) |
| AU (1) | AU2007334333B2 (enExample) |
| BR (1) | BRPI0720476B1 (enExample) |
| CA (1) | CA2672758C (enExample) |
| CO (1) | CO6230995A2 (enExample) |
| CR (1) | CR10889A (enExample) |
| DK (2) | DK2468290T3 (enExample) |
| EA (3) | EA035911B1 (enExample) |
| EC (1) | ECSP099514A (enExample) |
| ES (1) | ES2396734T3 (enExample) |
| HK (2) | HK1209624A1 (enExample) |
| HR (1) | HRP20121035T1 (enExample) |
| IL (5) | IL199451A (enExample) |
| ME (1) | ME02335B (enExample) |
| MX (2) | MX2009006651A (enExample) |
| MY (3) | MY162136A (enExample) |
| NZ (4) | NZ720955A (enExample) |
| PH (1) | PH12013500310B1 (enExample) |
| PL (2) | PL2468290T3 (enExample) |
| PT (1) | PT2124999E (enExample) |
| RS (1) | RS52537B (enExample) |
| SG (1) | SG10201702157QA (enExample) |
| SI (1) | SI2124999T1 (enExample) |
| UA (2) | UA116871C2 (enExample) |
| WO (1) | WO2008076437A2 (enExample) |
| ZA (2) | ZA200904454B (enExample) |
Families Citing this family (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6989276B2 (en) | 2001-05-10 | 2006-01-24 | Battelle Energy Alliance, Llc | Rapid classification of biological components |
| USRE46351E1 (en) | 2001-05-10 | 2017-03-28 | Battelle Energy Alliance, Llc | Antibody profiling sensitivity through increased reporter antibody layering |
| EP3489257A1 (en) | 2004-07-23 | 2019-05-29 | Acceleron Pharma Inc. | Actrii receptor polypeptides, methods and compositions |
| EP2781222B1 (en) | 2005-11-23 | 2017-08-02 | Acceleron Pharma, Inc. | Activin-actriia antagonists in use for promoting bone growth |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| US8895016B2 (en) * | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| US20100028332A1 (en) * | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
| WO2008076437A2 (en) * | 2006-12-18 | 2008-06-26 | Acceleron Pharma Inc. | Activin-actrii antagonists and uses for increasing red blood cell levels |
| CA2677007A1 (en) * | 2007-02-01 | 2008-08-07 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for treating or preventing breast cancer |
| TW201803890A (zh) | 2007-02-02 | 2018-02-01 | 艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| EP2481415B1 (en) | 2007-02-09 | 2019-09-11 | Acceleron Pharma Inc. | Pharmaceutical compositions comprising Activin-ActRIIA antagonists |
| US7947646B2 (en) | 2007-03-06 | 2011-05-24 | Amgen Inc. | Variant activin receptor polypeptides |
| US20080286881A1 (en) * | 2007-05-14 | 2008-11-20 | Apel William A | Compositions and methods for combining report antibodies |
| JP2010539236A (ja) | 2007-09-18 | 2010-12-16 | アクセルロン ファーマ， インコーポレイテッド | アクチビン−ＡｃｔＲＩＩａ拮抗薬およびＦＳＨ分泌を低減または阻害するための使用 |
| US8466187B2 (en) | 2007-09-18 | 2013-06-18 | Thermolife International, Llc | Amino acid compositions |
| CN102131822A (zh) | 2008-06-26 | 2011-07-20 | 阿塞勒隆制药公司 | 进行激活素-ActRIIa拮抗剂给药和监测受治疗患者的方法 |
| KR20110031951A (ko) * | 2008-06-26 | 2011-03-29 | 악셀레론 파마 인코포레이티드 | 액티빈-ａｃｔｒｉｉａ의 길항물질 및 적혈구 수준을 증가시키기 위한 이들의 용도 |
| TWI626945B (zh) * | 2008-08-14 | 2018-06-21 | 艾瑟勒朗法瑪公司 | 使用ｇｄｆ阱以增加紅血球水平 |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| AU2015202035B2 (en) * | 2008-08-14 | 2017-03-23 | Acceleron Pharma Inc. | Use of GDF traps to increase red blood cell levels |
| WO2010045518A1 (en) * | 2008-10-16 | 2010-04-22 | The Trustees Of The University Of Pennsylvania | Compositions containing thrombomodulin domains and uses thereof |
| NZ627111A (en) | 2008-11-26 | 2015-10-30 | Amgen Inc | Variants of activin iib receptor polypeptides and uses thereof |
| AU2010204985A1 (en) * | 2009-01-13 | 2011-08-04 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
| JP5912078B2 (ja) | 2009-06-08 | 2016-04-27 | アクセルロン ファーマ， インコーポレイテッド | 熱発生性脂肪細胞を増加させるための方法 |
| EP3290439B1 (en) | 2009-06-12 | 2020-09-02 | Acceleron Pharma Inc. | Truncated actriib-fc fusion proteins |
| CN102655872B (zh) * | 2009-08-13 | 2016-01-20 | 阿塞勒隆制药公司 | Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平 |
| JP6211767B2 (ja) * | 2009-09-09 | 2017-10-11 | アクセルロン ファーマ， インコーポレイテッド | ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用 |
| US8969009B2 (en) * | 2009-09-17 | 2015-03-03 | Vicki S. Thompson | Identification of discriminant proteins through antibody profiling, methods and apparatus for identifying an individual |
| US9410965B2 (en) * | 2009-09-17 | 2016-08-09 | Battelle Energy Alliance, Llc | Identification of discriminant proteins through antibody profiling, methods and apparatus for identifying an individual |
| WO2011056896A1 (en) * | 2009-11-03 | 2011-05-12 | Acceleron Pharma Inc. | Methods for treating fatty liver disease |
| EP3332796A1 (en) | 2009-11-17 | 2018-06-13 | Acceleron Pharma Inc. | Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| WO2012027065A2 (en) * | 2010-08-27 | 2012-03-01 | Celgene Corporation | Combination therapy for treatment of disease |
| ES3005233T3 (en) | 2010-10-01 | 2025-03-14 | Modernatx Inc | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| KR20130132824A (ko) | 2010-11-08 | 2013-12-05 | 악셀레론 파마 인코포레이티드 | Actriia 결합제 및 이의 용도 |
| US12612370B2 (en) | 2011-03-02 | 2026-04-28 | Thermolife International, Llc | Amino acid compositions |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2763701B1 (en) | 2011-10-03 | 2018-12-19 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| JP2015501844A (ja) | 2011-12-16 | 2015-01-19 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物 |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| WO2013151663A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of membrane proteins |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9809636B2 (en) | 2012-04-06 | 2017-11-07 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels comprising administering BMP9 |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| JP6214537B2 (ja) * | 2012-08-21 | 2017-10-25 | 国立大学法人九州大学 | 貧血患者の貧血の要因を検出するためのバイオマーカー |
| EP2912462B1 (en) * | 2012-10-24 | 2019-08-07 | Celgene Corporation | Biomarker for use in treating anemia |
| CA2889286A1 (en) * | 2012-10-24 | 2014-05-01 | Celgene Corporation | Methods for treating anemia |
| US10195249B2 (en) * | 2012-11-02 | 2019-02-05 | Celgene Corporation | Activin-ActRII antagonists and uses for treating bone and other disorders |
| ES2921623T3 (es) | 2012-11-26 | 2022-08-30 | Modernatx Inc | ARN modificado terminalmente |
| SG11201505960VA (en) | 2013-02-01 | 2015-08-28 | Santa Maria Biotherapeutics Inc | Administration of an anti-activin-a compound to a subject |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| EP3119418B1 (en) * | 2014-03-21 | 2022-02-23 | Acceleron Pharma Inc. | Composition for use in a method of treating or preventing anemia by inhibiting activin b and gdf11 |
| US10010498B2 (en) | 2014-06-04 | 2018-07-03 | Acceleron Pharma Inc. | Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins |
| KR102132144B1 (ko) | 2014-06-04 | 2020-07-09 | 악셀레론 파마 인코포레이티드 | 폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물 |
| MA40008A (fr) | 2014-06-13 | 2021-05-05 | Acceleron Pharma Inc | Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie |
| MA41052A (fr) * | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| CA2964808C (en) | 2014-10-30 | 2023-06-27 | Acceleron Pharma Inc. | Methods and compositions using gdf15 polypeptides for increasing red blood cells |
| MA41119A (fr) | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| TWI730949B (zh) * | 2014-12-03 | 2021-06-21 | 美商西建公司 | 活化素-ａｃｔｒｉｉ拮抗劑及治療貧血之用途 |
| US20180215801A1 (en) * | 2015-01-29 | 2018-08-02 | Board Of Trustees Of Michigan State University | Cryptic polypeptides and uses thereof |
| US20180031579A1 (en) | 2015-02-12 | 2018-02-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease |
| CN107636154A (zh) | 2015-03-26 | 2018-01-26 | 阿塞勒隆制药公司 | 促滤泡素抑制素相关的融合蛋白及其用途 |
| BR112017021510A2 (pt) * | 2015-04-06 | 2018-07-03 | Acceleron Pharma Inc | heteromultímeros do receptor tipo i e tipo ii da superfamília tgf-beta e sua utilização |
| SI3286206T1 (sl) | 2015-04-22 | 2021-07-30 | Biogen Ma Inc. | Novi hibridni proteini ligandske pasti actriib za zdravljenje bolezni zaradi izgube mišične mase |
| JP6976859B2 (ja) * | 2015-05-13 | 2021-12-08 | セルジーン コーポレイション | ＡｃｔＲＩＩリガンドトラップを用いたβ−サラセミアの治療 |
| EP3298034A4 (en) | 2015-05-20 | 2019-02-13 | Celgene Corporation | IN VITRO CELL CULTURE PROCEDURE FOR BETA THALASSEMIA BY MEANS OF ACTIVIN TYPE II RECEPTOR LIGANDS |
| US10563029B2 (en) * | 2015-07-06 | 2020-02-18 | Mitsubishi Gas Chemical Company, Inc. | Resin composition and prepreg, resin sheet, laminate, and printed circuit board |
| EP3370754B1 (en) | 2015-11-04 | 2026-04-29 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
| CA3005975A1 (en) | 2015-11-23 | 2017-06-01 | Acceleron Pharma Inc. | Methods for treating eye disorders |
| EP3439741B1 (en) * | 2016-04-06 | 2026-05-20 | Acceleron Pharma Inc | ACTRIIB:ALK7 HETEROMULTIMERS FOR THERAPEUTIC BODY WEIGHT REDUCTION |
| CN116531490A (zh) | 2016-07-15 | 2023-08-04 | 阿塞勒隆制药公司 | 用于治疗肺高血压的组合物和方法 |
| HUE067225T2 (hu) | 2016-07-27 | 2024-10-28 | Acceleron Pharma Inc | Mielofibrózis kezelésére szolgáló készítmények |
| JP6944768B2 (ja) | 2016-08-29 | 2021-10-06 | エア・ウォーター株式会社 | ペリクルの製造方法 |
| KR102761094B1 (ko) | 2016-10-05 | 2025-02-03 | 악셀레론 파마 인코포레이티드 | 변이체 actriib 단백질 및 이의 용도 |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| CN119241685A (zh) | 2016-11-10 | 2025-01-03 | 科乐斯疗法公司 | 激活素受体iia型变体及其使用方法 |
| SI3600415T1 (sl) | 2017-03-24 | 2026-01-30 | Novartis Ag | Protitelo proti aktivinskemu receptorju tipa ii za uporabo pri zdravljenju srčnega popuščanja |
| CN111801112A (zh) | 2017-11-09 | 2020-10-20 | 科乐斯疗法公司 | 激活素受体iia型变体及其使用方法 |
| KR20200109330A (ko) | 2018-01-12 | 2020-09-22 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iib 변이체 및 그의 사용 방법 |
| WO2019217715A1 (en) | 2018-05-09 | 2019-11-14 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| JP2022549506A (ja) | 2019-09-27 | 2022-11-25 | ディスク・メディシン・インコーポレイテッド | 骨髄線維症および関連状態を処置するための方法 |
| CA3162880A1 (en) | 2019-11-29 | 2021-06-03 | Kymab Limited | Treatment for physiological iron overload |
| CA3176735A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Activin receptor type ii chimeras and methods of use thereof |
| EP4121088A4 (en) | 2020-03-20 | 2024-07-03 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| EP4142769A4 (en) | 2020-04-28 | 2024-05-15 | Acceleron Pharma Inc. | ACTRII PROTEINS AND USE IN THE TREATMENT OF POSTCAPILLARY PULMONARY HYPERTENSION |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
| KR20230145103A (ko) | 2021-02-11 | 2023-10-17 | 써모라이프 인터내셔널, 엘엘씨 | 산화질소 기체의 투여 방법 |
| MX2024001246A (es) * | 2021-08-16 | 2024-02-13 | Thermolife Int Llc | Composiciones de suplemento de hierro y metodos de uso de las mismas. |
| WO2023141724A1 (en) | 2022-01-28 | 2023-08-03 | 35Pharma Inc. | Activin receptor type iib variants and uses thereof |
| EP4676515A1 (en) * | 2023-03-09 | 2026-01-14 | Merck Sharp & Dohme LLC | Formulations comprising actriia polypeptide variants |
| US20260092096A1 (en) | 2024-05-14 | 2026-04-02 | 35Pharma Inc. | Activin receptor type iib variants and uses thereof |
| WO2025250605A1 (en) * | 2024-05-31 | 2025-12-04 | Eli Lilly And Company | Acvr2a and acvr2b rna interference agents |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US71927A (en) * | 1867-12-10 | Improvement in apparatus fob turning on gas | ||
| JPH0637520B2 (ja) | 1985-07-03 | 1994-05-18 | 味の素株式会社 | ポリペプチド |
| US4973577A (en) | 1986-04-04 | 1990-11-27 | The Salk Institute For Biological Studies | FSH-releasing peptides |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| EP0548276A4 (en) * | 1990-09-13 | 1993-12-29 | Children's Hospital Medical Center Of Northern California | Method for increasing red blood cell production by treatment with activin or activin-related peptides |
| US5118667A (en) | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
| US6162896A (en) | 1991-05-10 | 2000-12-19 | The Salk Institute For Biological Studies | Recombinant vertebrate activin receptors |
| US5885794A (en) | 1991-05-10 | 1999-03-23 | The Salk Institute For Biological Studies | Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily |
| CA2086327A1 (en) | 1991-05-10 | 1992-11-11 | Lawrence S. Mathews | Cloning and recombinant production of receptor(s) of the activin/tgf- .beta. superfamily |
| US6692925B1 (en) | 1992-11-17 | 2004-02-17 | Ludwig Institute For Cancer Research | Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use |
| US5677196A (en) | 1993-05-18 | 1997-10-14 | University Of Utah Research Foundation | Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays |
| US5831050A (en) | 1993-06-07 | 1998-11-03 | Creative Biomolecules, Inc. | Morphogen cell surface receptor |
| AU701623B2 (en) | 1993-10-14 | 1999-02-04 | President And Fellows Of Harvard College | Method of inducing and maintaining neuronal cells |
| US5525490A (en) | 1994-03-29 | 1996-06-11 | Onyx Pharmaceuticals, Inc. | Reverse two-hybrid method |
| US5658876A (en) | 1994-04-28 | 1997-08-19 | The General Hospital Corporation | Activin antagonists as novel contraceptives |
| US5814565A (en) | 1995-02-23 | 1998-09-29 | University Of Utah Research Foundation | Integrated optic waveguide immunosensor |
| NZ502795A (en) | 1995-04-11 | 2001-09-28 | Gen Hospital Corp | Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems |
| EP0771873A3 (en) | 1995-10-27 | 1998-03-04 | Takeda Chemical Industries, Ltd. | Neuronal cell-specific receptor protein |
| US6231880B1 (en) | 1997-05-30 | 2001-05-15 | Susan P. Perrine | Compositions and administration of compositions for the treatment of blood disorders |
| AU8666398A (en) | 1997-08-01 | 1999-02-22 | Johns Hopkins University School Of Medicine, The | Methods to identify growth differentiation factor (gdf) receptors |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| US6696260B1 (en) | 1997-08-01 | 2004-02-24 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (GDF) binding proteins |
| US6891082B2 (en) | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| US6953662B2 (en) | 1997-08-29 | 2005-10-11 | Human Genome Sciences, Inc. | Follistatin-3 |
| NZ513642A (en) | 1999-01-21 | 2004-02-27 | Metamorphix Inc | Growth differentiation factor inhibitors and uses therefor |
| AU777783B2 (en) | 1999-04-19 | 2004-10-28 | Kyowa Hakko Kogyo Co. Ltd. | Proliferation inhibitor for androgen-independent tumor |
| US6468543B1 (en) | 1999-05-03 | 2002-10-22 | Zymogenetics, Inc. | Methods for promoting growth of bone using ZVEGF4 |
| NZ519546A (en) * | 1999-12-15 | 2005-07-29 | Res Dev Foundation | Betaglycan as an inhibin receptor and uses thereof |
| JP4487376B2 (ja) | 2000-03-31 | 2010-06-23 | 味の素株式会社 | 腎疾患治療剤 |
| EP2141243A3 (en) | 2000-10-16 | 2010-01-27 | Brystol-Myers Squibb Company | Protein scaffolds for antibody mimics and other binding proteins |
| WO2002043759A2 (en) | 2000-12-01 | 2002-06-06 | Wyeth | Method and composition for modulating bone growth |
| TWI329129B (en) | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
| JP4369662B2 (ja) | 2001-04-26 | 2009-11-25 | アビディア インコーポレイテッド | 単量体ドメインのコンビナトリアルライブラリー |
| AU2001286171B2 (en) | 2001-05-25 | 2008-01-10 | Serono Genetics Institute S.A. | Human CDNAs and proteins and uses thereof |
| AUPR638101A0 (en) | 2001-07-13 | 2001-08-09 | Bioa Pty Limited | Composition and method for treatment of disease |
| US6855344B2 (en) | 2001-07-17 | 2005-02-15 | Integrated Chinese Medicine Holdings, Ltd. | Compositions and methods for prostate and kidney health and disorders, an herbal preparation |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| US6784154B2 (en) | 2001-11-01 | 2004-08-31 | University Of Utah Research Foundation | Method of use of erythropoietin to treat ischemic acute renal failure |
| US20030144203A1 (en) | 2001-12-19 | 2003-07-31 | Voyager Pharmaceutical Corporation | Methods for slowing senescence and treating and preventing diseases associated with senescence |
| BR0307907A2 (pt) | 2002-02-21 | 2011-07-05 | Wyeth Corp | gasp1: proteìna contendo domìnio de folistatina |
| US20030219846A1 (en) * | 2002-02-28 | 2003-11-27 | Pfizer Inc. | Assay for activity of the ActRIIB kinase |
| JP2004121008A (ja) * | 2002-09-30 | 2004-04-22 | Toray Ind Inc | ネコアクチビンａおよびそのサブユニット並びにその製造法 |
| US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
| US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| WO2004086953A2 (en) | 2003-03-26 | 2004-10-14 | The Board Of Trustees Of The University Of Arkansas | Method for diagnosis and treatment of bone turnover |
| US20070184052A1 (en) | 2003-05-09 | 2007-08-09 | Lin Herbert Y | Soluble tgf-b type III receptor fusion proteins |
| JP5110877B2 (ja) | 2003-06-02 | 2012-12-26 | ワイス・エルエルシー | 神経筋障害を処置するための、コルチコステロイドと組み合わせたミオスタチン（ｇｄｆ８）インヒビターの使用 |
| WO2005009460A2 (en) * | 2003-07-25 | 2005-02-03 | Medexis, S.A. | Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer |
| JP2007530055A (ja) | 2004-03-26 | 2007-11-01 | アクセルロン ファーマ インコーポレーテッド | Ｂｍｐ−３プロペプチドおよび関連する方法 |
| WO2005097825A2 (en) | 2004-03-31 | 2005-10-20 | Xencor, Inc. | Bmp-7 variants with improved properties |
| EP1771557B1 (en) | 2004-06-24 | 2014-12-31 | Acceleron Pharma Inc. | GDF3 Propeptides and Related Methods |
| EP3489257A1 (en) | 2004-07-23 | 2019-05-29 | Acceleron Pharma Inc. | Actrii receptor polypeptides, methods and compositions |
| CA2581896C (en) | 2004-09-29 | 2015-11-10 | Mount Sinai School Of Medicine Of New York University | Fsh and fsh receptor modulator compositions and methods for inhibiting osteoclastic bone resorption and bone loss in osteoporosis |
| EP1824796A4 (en) | 2004-11-16 | 2010-02-17 | Avidia Res Inst | PROTEIN SKELETONS AND USES THEREOF |
| NZ538097A (en) | 2005-02-07 | 2006-07-28 | Ovita Ltd | Method and compositions for improving wound healing |
| US7968091B2 (en) | 2005-02-16 | 2011-06-28 | The General Hospital Corporation | Methods and compositions to regulate iron metabolism |
| KR20080003929A (ko) * | 2005-04-26 | 2008-01-08 | 아지노모토 가부시키가이샤 | 골수 적혈구 전구 세포 분화 촉진제 |
| US8067562B2 (en) | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
| EP2781222B1 (en) | 2005-11-23 | 2017-08-02 | Acceleron Pharma, Inc. | Activin-actriia antagonists in use for promoting bone growth |
| EP1968621A2 (en) | 2005-12-06 | 2008-09-17 | Amgen Inc. | Uses of myostatin antagonists |
| US7361512B2 (en) | 2006-01-20 | 2008-04-22 | Beckman Coulter, Inc. | Low hemoglobin concentration cell percentage and method of use in detection of iron deficiency |
| AU2007249827A1 (en) | 2006-05-09 | 2007-11-22 | Colorado State University Research Foundation | Methods for treating blood disorders |
| AU2007275606B9 (en) | 2006-07-21 | 2013-09-26 | Lyne Laboratories, Inc. | Liquid compositions of calcium acetate |
| CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
| US7547781B2 (en) | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
| WO2008060139A1 (en) | 2006-11-17 | 2008-05-22 | Erasmus University Medical Center Rotterdam | Methods for controlling mineralization of extracellular matrix, therapeutic methods based thereon and medicaments for use therein |
| WO2008076437A2 (en) * | 2006-12-18 | 2008-06-26 | Acceleron Pharma Inc. | Activin-actrii antagonists and uses for increasing red blood cell levels |
| US8895016B2 (en) * | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| CA2677007A1 (en) | 2007-02-01 | 2008-08-07 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for treating or preventing breast cancer |
| TW201803890A (zh) | 2007-02-02 | 2018-02-01 | 艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| EP2481415B1 (en) | 2007-02-09 | 2019-09-11 | Acceleron Pharma Inc. | Pharmaceutical compositions comprising Activin-ActRIIA antagonists |
| US7947646B2 (en) | 2007-03-06 | 2011-05-24 | Amgen Inc. | Variant activin receptor polypeptides |
| US20090017019A1 (en) | 2007-06-01 | 2009-01-15 | Wyeth | Methods and compositions for modulating bmp-10 activity |
| GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
| TW200911237A (en) | 2007-08-03 | 2009-03-16 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
| JP2010539236A (ja) | 2007-09-18 | 2010-12-16 | アクセルロン ファーマ， インコーポレイテッド | アクチビン−ＡｃｔＲＩＩａ拮抗薬およびＦＳＨ分泌を低減または阻害するための使用 |
| PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| AU2009244308A1 (en) | 2008-05-06 | 2009-11-12 | Joslin Diabetes Center, Inc. | Methods and compositions for inducing brown adipogenesis |
-
2007
- 2007-12-18 WO PCT/US2007/025868 patent/WO2008076437A2/en not_active Ceased
- 2007-12-18 MX MX2009006651A patent/MX2009006651A/es active IP Right Grant
- 2007-12-18 EP EP07863068A patent/EP2124999B1/en active Active
- 2007-12-18 NZ NZ720955A patent/NZ720955A/en unknown
- 2007-12-18 PL PL11195130T patent/PL2468290T3/pl unknown
- 2007-12-18 CN CN201610144786.3A patent/CN105797135A/zh active Pending
- 2007-12-18 KR KR1020167001731A patent/KR101831534B1/ko active Active
- 2007-12-18 MY MYPI20092540A patent/MY162136A/en unknown
- 2007-12-18 KR KR1020157013795A patent/KR101803620B1/ko active Active
- 2007-12-18 KR KR1020217005960A patent/KR20210027508A/ko not_active Ceased
- 2007-12-18 PL PL07863068T patent/PL2124999T3/pl unknown
- 2007-12-18 MX MX2012002498A patent/MX373050B/es unknown
- 2007-12-18 CN CN201610145040.4A patent/CN105582521A/zh active Pending
- 2007-12-18 AU AU2007334333A patent/AU2007334333B2/en active Active
- 2007-12-18 DK DK11195130.7T patent/DK2468290T3/en active
- 2007-12-18 EA EA201201199A patent/EA035911B1/ru not_active IP Right Cessation
- 2007-12-18 JP JP2009542880A patent/JP5415279B2/ja active Active
- 2007-12-18 CN CN201410670950.5A patent/CN104524548A/zh active Pending
- 2007-12-18 ME MEP-2016-200A patent/ME02335B/me unknown
- 2007-12-18 PT PT78630688T patent/PT2124999E/pt unknown
- 2007-12-18 US US12/002,872 patent/US7988973B2/en active Active
- 2007-12-18 UA UAA201214689A patent/UA116871C2/uk unknown
- 2007-12-18 SG SG10201702157QA patent/SG10201702157QA/en unknown
- 2007-12-18 KR KR1020097014226A patent/KR101688228B1/ko active Active
- 2007-12-18 MY MYPI2016001928A patent/MY188973A/en unknown
- 2007-12-18 NZ NZ577847A patent/NZ577847A/en unknown
- 2007-12-18 DK DK07863068.8T patent/DK2124999T3/da active
- 2007-12-18 NZ NZ617196A patent/NZ617196A/en unknown
- 2007-12-18 HR HRP20121035TT patent/HRP20121035T1/hr unknown
- 2007-12-18 EP EP11195130.7A patent/EP2468290B1/en active Active
- 2007-12-18 EP EP11195140.6A patent/EP2468291B1/en active Active
- 2007-12-18 EP EP17182870.0A patent/EP3320911B1/en active Active
- 2007-12-18 EP EP11195282A patent/EP2446896A1/en not_active Withdrawn
- 2007-12-18 SI SI200731110T patent/SI2124999T1/sl unknown
- 2007-12-18 EP EP21205033.0A patent/EP4026553A1/en not_active Withdrawn
- 2007-12-18 MY MYPI2013002844A patent/MY170509A/en unknown
- 2007-12-18 EA EA200970603A patent/EA018037B1/ru unknown
- 2007-12-18 UA UAA200906746A patent/UA101309C2/ru unknown
- 2007-12-18 KR KR1020187004410A patent/KR20180019768A/ko not_active Ceased
- 2007-12-18 BR BRPI0720476-0A patent/BRPI0720476B1/pt active IP Right Grant
- 2007-12-18 PH PH1/2013/500310A patent/PH12013500310B1/en unknown
- 2007-12-18 EA EA202091230A patent/EA202091230A3/ru unknown
- 2007-12-18 ES ES07863068T patent/ES2396734T3/es active Active
- 2007-12-18 NZ NZ707292A patent/NZ707292A/en unknown
- 2007-12-18 CA CA2672758A patent/CA2672758C/en active Active
- 2007-12-18 KR KR1020207006948A patent/KR102223231B1/ko active Active
- 2007-12-18 RS RS20120548A patent/RS52537B/sr unknown
- 2007-12-19 CN CN200780051416.4A patent/CN101687015B/zh active Active
-
2008
- 2008-09-29 US US12/286,381 patent/US20100204092A1/en not_active Abandoned
- 2008-09-29 US US12/286,333 patent/US8007809B2/en active Active
-
2009
- 2009-06-18 IL IL199451A patent/IL199451A/en active IP Right Grant
- 2009-06-24 CR CR10889A patent/CR10889A/es unknown
- 2009-06-25 ZA ZA2009/04454A patent/ZA200904454B/en unknown
- 2009-07-09 CO CO09071017A patent/CO6230995A2/es not_active Application Discontinuation
- 2009-07-14 EC EC2009009514A patent/ECSP099514A/es unknown
-
2011
- 2011-07-22 US US13/189,353 patent/US20120052067A1/en not_active Abandoned
-
2012
- 2012-03-19 ZA ZA2012/02027A patent/ZA201202027B/en unknown
-
2013
- 2013-03-18 JP JP2013055102A patent/JP5865281B2/ja active Active
- 2013-11-26 JP JP2013243668A patent/JP2014040483A/ja active Pending
-
2015
- 2015-08-12 IL IL240523A patent/IL240523A/en active IP Right Grant
- 2015-08-12 IL IL240524A patent/IL240524A/en active IP Right Grant
- 2015-10-22 HK HK15110382.8A patent/HK1209624A1/xx unknown
- 2015-10-27 JP JP2015211115A patent/JP2016020391A/ja active Pending
-
2017
- 2017-02-03 JP JP2017018409A patent/JP2017075187A/ja active Pending
- 2017-06-19 JP JP2017119494A patent/JP2017155064A/ja not_active Withdrawn
- 2017-12-11 IL IL256247A patent/IL256247B/en unknown
-
2018
- 2018-10-31 HK HK18113934.2A patent/HK1254840A1/en unknown
-
2019
- 2019-01-04 US US16/240,276 patent/US20200031903A1/en not_active Abandoned
- 2019-03-12 JP JP2019044553A patent/JP2019089850A/ja not_active Withdrawn
-
2020
- 2020-12-23 US US17/132,024 patent/US20210355191A1/en not_active Abandoned
-
2021
- 2021-03-01 JP JP2021032007A patent/JP2021080290A/ja active Pending
- 2021-07-07 IL IL284693A patent/IL284693A/en unknown
- 2021-08-05 US US17/395,365 patent/US20220204588A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6807132B2 (ja) | 組換えエリスロポエチンと部分的に組合されたｉｌ−１インヒビターおよびｔｎｆアンタゴニストの貧血治療用途 | |
| JP2014040483A5 (enExample) | ||
| JP2013504589A5 (enExample) | ||
| ME02335B (me) | Activin-actrii antagonisti i upotreba za liječenje anemije | |
| JP2008500373A5 (enExample) | ||
| IL251834B2 (en) | Pharmaceutical compositions containing peptide variants and methods of using them | |
| CN101588820A (zh) | α-乳清蛋白组合物 | |
| JP7280619B2 (ja) | ペプチド組成物 | |
| RS67940B1 (sr) | Materijali i postupci za lečenje friedreich-ove ataksije | |
| US11299528B2 (en) | Long acting TRAIL receptor agonists for treatment of autoimmune diseases | |
| DE69131579T2 (de) | Synthetisches antigen einer alternden zelle | |
| US20210324043A1 (en) | ApoC-II Mimetic Peptides | |
| JP2000502569A (ja) | Ｏｂタンパク質レセプター及び関連組成物と関連方法 | |
| JP2003533538A5 (enExample) | ||
| AU2005231822A1 (en) | Methods of reducing aggregation of IL-1ra | |
| CN114621357A (zh) | 一种带状疱疹亚单位疫苗及其制备方法 | |
| JPWO2001080891A1 (ja) | 間質性肺炎治療薬および当該疾病の動物モデルの作成方法並びにそれを用いるスクリーニング方法 | |
| KR20070004781A (ko) | 인터페론-타우를 포함하는 약학적 조성물 | |
| JP2000336038A (ja) | 肝臓保護剤 | |
| RU2420308C2 (ru) | Стабилизированные композиции ил-21 | |
| JP2017509602A5 (enExample) | ||
| JP2024540220A (ja) | Ｄｓｇ２組成物及び方法 | |
| PT91500A (pt) | Processo para a preparacao de antigenio de nefrite clonado | |
| CN104415328A (zh) | 异源动物细胞因子突变体疫苗及其应用 | |
| JP2006206524A (ja) | 可溶化インターロイキン１８レセプター及び医薬組成物並びに疾患の診断方法 |